Search 

Fat and muscle measurement for the obesity and aging markets, the two largest health problem areas. AMRA is a spin-off company from CMIV in Linköping.

1.5 billion people in the world has overweight or obesity and it’s well known today that too much abdominal fat is dangerous and increases the risk for many diseases, but still there are no accurate and cost effective fat measurement tools available.

AMRA has developed such a tool for automatic measurement of both fat and muscle volumes, based upon a short; 6 minutes scan in a MR scanner

We can then build a 3D model of the human body where it’s possible to measure the amount of fat or muscle volume in every pixel (voxel since it’s 3D) It’s then easy for us to automatically measure the area of interest, e.g. the amount of dangerous adipose fat or the muscle volume in the legs. With this method it’s easy to do comparisons of muscles before and after a rehabilitation program or fat volume after a life style change.

Our tool is 15-20 times quicker compare to current methods and much more accurate.

Together with General Electric we have done successful studies in UK and GE are now introducing AMRA to the key opinion leaders in the obesity area who will test our products.

AMRAs goal is to develop a number of SW applications for different clinical usage. We expect that AMRA obesity application will be needed in most hospitals in the world.

Our short-term strategy is to approach the research market with a Cloud based analysis service model. We are in negotiations with our first paying customer who would like to do 100.000 analyses. This will be an excellent way to finance our company, to get study data for CE/FDA certification and to establish AMRA as the standard for fat and muscle measurement.

We are looking for financing to build up our Cloud based analysis services.

Beddit develops and markets revolutionary products for sleep and wellness tracking. Utilizing special sensor technology and sophisticated signal analysis algorithms, Beddit has created products for tracking of sleep, heart rate and breathing without any disturbing wearable sensors. Beddit products are globally used by medical and training professionals as well as by consumers. Beddit (founded in 2006) has offices in Finland and Silicon Valley. 

Company aim is to produce high- tech medical solutions especially for reliable assessment and training of muscular strength.

Business idea is to offer solutions for safe and rapid recovery of patient’s functional ability in musculoskeletal rehabilitation enabling cost-effectiveness and increasing productivity in primary care profiting both end-user and health care provider.

The team know-how consist professional expertise on exercise physiology, engineering, as well as software and project management. In order to maximize full potential of product commercialization we are looking for complementary core expertise and supportive financing for successful products launch and internationalization efforts. 

Blueprint Genetics provides genetic diagnostics of rare diseases. The products are targeted for healthcare professionals and researchers. We sequence and interpret customers’ samples that are sent to the Blueprint laboratory and we report results online in 21 days after receiving the sample. Blueprint is able to cut the prices of rare diseases genetic testing by 15-70% while increasing quality and providing a statement that is backed with clinical expertise.

Blueprint Genetics was founded during summer 2012 and is currently backed up by angel investors. The company applies a revolutionary targeted DNA sequencing method developed in Stanford and published in the Nature. The company has just launched its first ten products and started the sales of clinical grade diagnostics. The company has an extensive product roadmap covering a long list of different hereditary disease groups. The first products are diagnostics for hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases.

Bone Index Finland Ltd. provides patented, reliable and cost effective solution for the growing need of osteoporosis diagnostics at primary healthcare.

Quality and safety are essential part of our business. Bone Index Finland has ISO 13485 certified Quality System as a medical device manufacturer. Products manufactured by us fulfill the requirements of Medical Device Directive (MDD 93/42/EEC).

It is estimated that over 75% of osteoporotic patients are not diagnosed nor receive treatment for their condition because the diagnostics is done in special healthcare. Our solution to fight this problem, Bindex®, is validated against prevailing gold standard in diagnostics (axial DXA) at special healthcare by using international guidelines. Therefore Bindex® results are comparable to axial DXA.

By using the world’s first pocket size instrument for bone densitometry, Bindex®, the osteoporosis can be diagnosed wherever you want!

Cognuse is developing solutions for the mental healthcare industry.

Our core product platform CognuseManager is an evidence-based patient-centric tool for cognitive rehabilitation in the executive functions domain. It allows TBI and stroke patients to continue their rehabilitation processes in the home setting on most modern devices with a touch screen and gives the therapist an opportunity to monitor their progress in real-time and adjust the training plans, when necessary.

While the initial set of exercises focused on real-life tasks, we are now expanding into other cognitive domains to provide a full suite of services for the rehabilitation flow.

Our customers include hospitals, clinics, independent professionals and home users in neuropsychological rehabilitation, mental healthcare and other related sectors.

Ferrosan Medical Devices comprises two companies that both provide a range of innovative products used by health care professionals in the fields of surgery and diagnostics. Our technology includes Biomaterials used as haemostatic agent for surgery to control bleeding, and miniature Electromechanics used in devices for minimally invasive surgery and drug delivery.

Fluence Therapeutics is commercializing photodynamic therapy for the treatment of psoriasis and other skin diseases.

We have successfully completed Phase Ia studies and are seeking funding for the completion of a Phase Ib/IIa proof of concept study in Tampere, Finland.

Current therapies are not adequate for the treatment of difficult cases of psoriasis.  Current light therapies use UV light, which is a known carcinogen, requires many treatments and results in premature photoaging.  Systemic pharmaceuticals globally suppress the immune system, resulting in increased rates of infection and certain kinds of cancers. 

Our therapy uses a novel photosensitizer which is activated by harmless red light and, unlike ALA PDT, does not result in pain or residual photosensitivity.  It can treat multiple, large lesions simultaneously.  It is totally inert unless activated by visible red light.  When activated, it preferentially kills activated t cells over other skin cells.